David Celestial, DO
Family Medicine · Columbus, GANPI 1982691952
Payments from drug & device makers
Across 636 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- Bayer$904
- GSK$846
- plus $4K from 32 others
What the payments were for
- Food & beverage$10,925100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 100 | $1,543 |
| AstraZeneca | 85 | $1,510 |
| Lilly USA, LLC | 95 | $1,298 |
| Boehringer Ingelheim | 54 | $1,029 |
| Bayer | 36 | $904 |
| GSK | 51 | $846 |
| Astellas Pharma US Inc | 22 | $497 |
| Sanofi-aventis U.S. LLC | 26 | $475 |
| Pfizer | 37 | $431 |
| Abbott | 17 | $375 |
| Amgen(2 entities) | 19 | $323 |
| Johnson & Johnson | 18 | $312 |
| AbbVie(2 entities) | 16 | $257 |
| Merck | 12 | $214 |
| Otsuka America Pharmaceutical, Inc. | 5 | $109 |
| Esperion Therapeutics, Inc. | 6 | $96 |
| Sumitomo Pharma America, Inc. | 3 | $76 |
| Novartis | 3 | $64 |
| Idorsia Pharmaceuticals US Inc | 4 | $63 |
| Dexcom, Inc. | 3 | $52 |
| Amarin Pharma, Inc. | 2 | $45 |
| Radius Health, Inc. | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Medtronic | 1 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Philips North America LLC | 2 | $30 |
| Zyla Life Sciences, Inc. | 2 | $26 |
| Exact Sciences | 1 | $25 |
| Vertex | 1 | $22 |
| Braemar Manufacturing, LLC | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Intuitive Surgical | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| RTI Surgical, Inc | 1 | $16 |
| Abiomed | 1 | $15 |
| Vivus LLC | 1 | $15 |
| Alvogen Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$10,925 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 164 | $196,230 |
| RybelsusSemaglutide | 36 | $84,295 |
| FarxigaDapagliflozin Propanediol | 59 | $71,800 |
| MounjaroTirzepatide | 54 | $61,045 |
| OzempicSemaglutide | 41 | $51,268 |
| EliquisApixaban | 34 | $44,016 |
| MyrbetriqMirabegron | 28 | $30,095 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $30,002 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $24,129 |
| TrulicityDulaglutide | 11 | $10,680 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $8,831 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $7,124 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $7,017 |
| Losartan Potassium | 576 | $5,774 |
| Levothyroxine Sodium | 403 | $4,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,029 | $196,230164 claims |
| Novo NordiskRybelsus, Ozempic | $1,543 | $135,56377 claims |
| AstraZenecaFarxiga | $1,510 | $71,80059 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,298 | $71,72665 claims |
| PfizerEliquis | $431 | $44,01634 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $846 | $38,83348 claims |
| Astellas Pharma US IncMyrbetriq | $497 | $30,09528 claims |
| AbbVieSynthroid | $257 | $2,89935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Columbus
- Joseph SurberColumbus$16.6M
- Jeffrey KingsleyColumbus$8.1M
- Bantwal BaligaColumbus$117K
- Megbewe OkorobaColumbus$61K
- Kimberly Brown-GullattColumbus$35K
- Angela RitterGainesville$15.8M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.